Aceruloplasminemia

Aceruloplasminemia is a disorder in which iron gradually accumulates in the brain and other organs. Iron accumulation in the brain results in neurological problems that generally appear in adulthood and worsen over time.

People with aceruloplasminemia develop a variety of movement problems. They may experience involuntary muscle contractions (dystonia) of the head and neck, resulting in repetitive movements and contortions. Other involuntary movements may also occur, such as rhythmic shaking (tremors), jerking movements (chorea), eyelid twitching (blepharospasm), and grimacing. Affected individuals may also have difficulty with coordination (ataxia). Some develop psychiatric problems and a decline of intellectual function (dementia) in their forties or fifties.

In addition to neurological problems, affected individuals may have diabetes mellitus caused by iron damage to cells in the pancreas that make insulin, a hormone that helps control blood sugar levels. Iron accumulation in the pancreas reduces the cells' ability to make insulin, which impairs blood sugar regulation and leads to the signs and symptoms of diabetes.

Iron accumulation in the tissues and organs results in a corresponding shortage (deficiency) of iron in the blood, leading to a shortage of red blood cells (anemia). Anemia and diabetes usually occur by the time an affected person is in his or her twenties.

Affected individuals also have changes in the light-sensitive tissue at the back of the eye (retina) caused by excess iron. The changes result in small opaque spots and areas of tissue degeneration (atrophy) around the edges of the retina. These abnormalities usually do not affect vision but can be observed during an eye examination.

The specific features of aceruloplasminemia and their severity may vary, even within the same family.

Frequency

Aceruloplasminemia has been seen worldwide, but its overall prevalence is unknown. Studies in Japan have estimated that approximately 1 in 2 million adults in this population are affected.

Causes

Mutations in the CP gene cause aceruloplasminemia. The CP gene provides instructions for making a protein called ceruloplasmin, which is involved in iron transport and processing. Ceruloplasmin helps move iron from the organs and tissues of
the body and prepares it for incorporation into a molecule called transferrin, which transports it to red blood cells to help carry oxygen.

CP gene mutations result in the production of ceruloplasmin protein that is unstable or nonfunctional, or they prevent the protein from being released (secreted) by the cells in which it is made. When ceruloplasmin is unavailable, transport of iron out of the body's tissues is impaired. The resulting iron accumulation damages cells in those tissues, leading to neurological dysfunction, and the other health problems seen in aceruloplasminemia.

Inheritance Pattern
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition
- deficiency of ferroxidase
- familial apoceruloplasmin deficiency
- hereditary ceruloplasmin deficiency
- hypoceruloplasminemia
- systemic hemosiderosis due to aceruloplasminemia

Diagnosis & Management
Genetic Testing Information
- What is genetic testing? /primer/testing/genetictesting

Other Diagnosis and Management Resources

Additional Information & Resources
Health Information from MedlinePlus
Genetic and Rare Diseases Information Center

- Aceruloplasminemia
  https://rarediseases.info.nih.gov/diseases/9499/aceruloplasminemia

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Neurodegeneration with Brain Iron Accumulation Information Page
  https://www.ninds.nih.gov/Disorders/All-Disorders/Neurodegeneration-Brain-Iron-Accumulation-Information-Page

Educational Resources

- Orphanet: Aceruloplasminemia
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=48818

Patient Support and Advocacy Resources

- National Organization for Rare Disorders
  https://rarediseases.org/rare-diseases/aceruloplasminemia/
- NBIA Disorders Association
  https://www.nbiadisorders.org/

Clinical Information from GeneReviews

- Aceruloplasminemia
  https://www.ncbi.nlm.nih.gov/books/NBK1493

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28aceruloplasminemia%5BTIAB  %5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last +1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- ACERULOPLASMINEMIA
  http://omim.org/entry/604290

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17179893
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12614942
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12055353
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16629161

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16775387

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17637479

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17367269

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14719552

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12382203

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15105272

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16269323

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15105274

Reprinted from Genetics Home Reference:

Reviewed: October 2013
Published: March 19, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services